Hematology

However, a survival benefit was observed with using a signaling inhibitor in general for patients with angioimmunoblastic T-cell lymphoma.

The authors note that CAR-T cell therapy could change the treatment standard for patients with DLBCL, who previously had few options if standard chemotherapy treatment was ineffective.

The model may help clinicians identify patients who would benefit from disease-specific therapies or enrollment into clinical trials.

The pharmacist can help patients to manage symptoms throughout the entire treatment journey.

Expert breaks down these findings and more from the GLAMM1 study at the 2023 ASH Annual Meeting.

This is the first trial to show that a measurable residual disease (MRD)–guided approach with treatment beyond MRD negativity has a significant advantage over chemotherapy, both in terms of progression-free survival and overall survival.

The study results shine a light on the potential need for further policy changes that promote gender equity and bridge the gap in R01 funding awarded to female applicants.

Median overall survival is set to be more than 2 years, which is more than double the overall survival of current frontline therapies.

He also provides insight for students training in classical hematology, oncology hematology, or oncology pharmacy.

The efficacy of treatments, which is the outcomes in the ideal clinical trial setting, are known to often be better than the effectiveness of those treatments, which are the outcomes of patients in the real-world setting.

The study findings have implications for the identification of novel pathways with which to selectively target folate-metabolism blood cancers.

The president highlights a new curative treatment option for sickle cell disease while also expanding on the changing treatment landscape for hematologic conditions.

This FDA approval represents the first cell-based gene therapies for the treatment of sickle cell disease in patients 12 years of age and older.

ASH is happening December 9 through 12 in San Diego, California.

During clinical trials, individuals treated with iptacopan had increased hemoglobin levels and did not need to receive blood transfusions.

Currently, there is no established standard of care treatment approach of HGBL, with frontline interventions consisting of chemo-immunotherapies.

Pirtobrutinib is the first and only non-covalent BTK inhibitor to be approved by the FDA and is indicated for adult patients who already received at least 2 prior lines of therapy.

This is KRP203’s second Orphan Drug Designation and it is the only S1P receptor modulator being developed as an adjunctive and maintenance treatment for blood cancers.

Belantamab mafodotin (Blenrep; GlaxoSmithKline) demonstrated that, when combined with bortezomib and dexamethasone (BorDex), the time to disease progression or death was extended.

Although vaccination status and the severity of COVID-19 infection were not correlated, the timing of vaccine administration influenced whether patients had severe COVID-19 infection.

The update followed results from the phase 1/2 EPCORE NHL-1 clinical trial evaluating the safety and preliminary efficacy of the drug, including in individuals with relapsed or refractory follicular lymphoma.

In crafting a patient-centered regimen, the convergence of expertise from physicians and pharmacists, paired with the values and preferences of patients, becomes paramount.

Pharmacies have the potential to introduce testing services, promote public health campaigns, collaborate with anemia-led clinics, and get more prescribing rights to diagnose anemia.

The review comes after phase 3 trial results that indicate an improvement in overall survival and progression-free survival, reducing the risk of disease progression and death.

The study authors suggest that future research should instead emphasize event rates and patient-reported outcomes to better evaluate the tolerability and frequency of AEs.

The acceptance comes after results from TRANSCEND CLL 004, which is the first trial to demonstrate clinical benefit with a CAR T cell therapy in patients who were previously treated for CLL or SLL.

The on-demand enzyme replacement therapy reduced acute thrombotic thrombocytopenic purpura events in patients who experience potentially fatal blood clotting.

The study findings provide the first in-depth look at the relationship between chromosomal changes in tumor cells and immune components of the tumor microenvironment.

Data show patients are willing to accept associated risks for a chance at a cure.

Leung discusses that various cancer types and drugs can cause thrombotic microangiopathy and impact kidney health and the renal complications connected to hematologic malignancies.